FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W89277110> ?p ?o ?g. }

• W89277110 abstract "Natural and synthetic retinoids have proved to be effective in the treatment and prevention of various human cancers. In the present study, we investigated the effect of retinoids on Epstein-Barr virus (EBV)-infected lymphoblastoid cell lines (LCLs), since these cells closely resemble those that give rise to EBV-related lymphoproliferative disorders in the immunosuppressed host. All six compounds tested inhibited LCL proliferation with no significant direct cytotoxicity, but 9-cis-retinoic acid (RA), 13-cis-RA, and all-trans-RA (ATRA) were markedly more efficacious than Ro40–8757, Ro13–6298, and etretinate. The antiproliferative action of the three most effective compounds was confirmed in a large panel of LCLs, thus appearing as a generalized phenomenon in these cells. LCL growth was irreversibly inhibited even after 2 days of treatment at drug concentrations corresponding to therapeutically achievable plasma levels. Retinoid-treated cells showed a marked downregulation of CD71 and a decreased S-phase compartment with a parallel accumulation in Gzero/ G1 phases. These cell cycle perturbations were associated with the upregulation of p27 Kip1, a nuclear protein that controls entrance and progression through the cell cycle by inhibiting several cyclin/cyclin-dependent kinase complexes. Unlike what is observed in other systems, the antiproliferative effect exerted by retinoids on LCLs was not due to the acquisition of a terminally differentiated status. In fact, retinoid-induced modifications of cell morphology, phenotype (downregulation of CD19, HLA-DR, and s-Ig, and increased expression of CD38 and c-Ig), and IgM production were late events, highly heterogeneous, and often slightly relevant, being therefore only partially indicative of a drug-related differentiative process. Moreover, EBV-encoded EBV nuclear antigen-2 and latent membrane protein-1 proteins were inconstantly downregulated by retinoids, indicating that their growth-inhibitory effect is not mediated by a direct modulation of viral latent antigen expression. The strong antiproliferative activity exerted by retinoids in our experimental model indicates that these compounds may represent a useful tool in the medical management of EBV-related lymphoproliferative disorders of immunosuppressed patients." @default.
• W89277110 created "2016-06-24" @default.
• W89277110 creator A5004832352 @default.
• W89277110 creator A5011146110 @default.
• W89277110 creator A5013492063 @default.
• W89277110 creator A5027726048 @default.
• W89277110 creator A5043970629 @default.
• W89277110 creator A5059617864 @default.
• W89277110 creator A5071674836 @default.
• W89277110 creator A5074389296 @default.
• W89277110 creator A5080767766 @default.
• W89277110 creator A5082360075 @default.
• W89277110 date "1996-10-15" @default.
• W89277110 modified "2023-09-29" @default.
• W89277110 title "Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus- immortalized B lymphocytes" @default.
• W89277110 cites W1493512966 @default.
• W89277110 cites W1524097176 @default.
• W89277110 cites W1595020114 @default.
• W89277110 cites W1598586133 @default.
• W89277110 cites W174661090 @default.
• W89277110 cites W17800351 @default.
• W89277110 cites W1839710111 @default.
• W89277110 cites W1844848296 @default.
• W89277110 cites W1975208051 @default.
• W89277110 cites W1975324295 @default.
• W89277110 cites W1979129905 @default.
• W89277110 cites W1980930194 @default.
• W89277110 cites W1985148567 @default.
• W89277110 cites W2001224935 @default.
• W89277110 cites W2005166009 @default.
• W89277110 cites W2011848967 @default.
• W89277110 cites W2015404822 @default.
• W89277110 cites W2016548488 @default.
• W89277110 cites W2021876324 @default.
• W89277110 cites W2024226585 @default.
• W89277110 cites W2043467656 @default.
• W89277110 cites W2061157878 @default.
• W89277110 cites W2070377570 @default.
• W89277110 cites W2079199354 @default.
• W89277110 cites W2090180123 @default.
• W89277110 cites W2100268767 @default.
• W89277110 cites W2124288486 @default.
• W89277110 cites W2150930737 @default.
• W89277110 cites W2171464968 @default.
• W89277110 cites W2407345634 @default.
• W89277110 cites W2433402730 @default.
• W89277110 cites W8133033 @default.
• W89277110 cites W962288603 @default.
• W89277110 cites W2418089685 @default.
• W89277110 doi "https://doi.org/10.1182/blood.v88.8.3147.bloodjournal8883147" @default.
• W89277110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8874215" @default.
• W89277110 hasPublicationYear "1996" @default.
• W89277110 type Work @default.
• W89277110 sameAs 89277110 @default.
• W89277110 citedByCount "31" @default.
• W89277110 countsByYear W892771102013 @default.
• W89277110 countsByYear W892771102014 @default.
• W89277110 countsByYear W892771102019 @default.
• W89277110 countsByYear W892771102022 @default.
• W89277110 crossrefType "journal-article" @default.
• W89277110 hasAuthorship W89277110A5004832352 @default.
• W89277110 hasAuthorship W89277110A5011146110 @default.
• W89277110 hasAuthorship W89277110A5013492063 @default.
• W89277110 hasAuthorship W89277110A5027726048 @default.
• W89277110 hasAuthorship W89277110A5043970629 @default.
• W89277110 hasAuthorship W89277110A5059617864 @default.
• W89277110 hasAuthorship W89277110A5071674836 @default.
• W89277110 hasAuthorship W89277110A5074389296 @default.
• W89277110 hasAuthorship W89277110A5080767766 @default.
• W89277110 hasAuthorship W89277110A5082360075 @default.
• W89277110 hasBestOaLocation W892771101 @default.
• W89277110 hasConcept C104317684 @default.
• W89277110 hasConcept C127561419 @default.
• W89277110 hasConcept C1491633281 @default.
• W89277110 hasConcept C153911025 @default.
• W89277110 hasConcept C159654299 @default.
• W89277110 hasConcept C203014093 @default.
• W89277110 hasConcept C2522874641 @default.
• W89277110 hasConcept C2775954498 @default.
• W89277110 hasConcept C2776705134 @default.
• W89277110 hasConcept C2778957590 @default.
• W89277110 hasConcept C2780564577 @default.
• W89277110 hasConcept C2781121885 @default.
• W89277110 hasConcept C2781375147 @default.
• W89277110 hasConcept C29537977 @default.
• W89277110 hasConcept C502942594 @default.
• W89277110 hasConcept C54355233 @default.
• W89277110 hasConcept C55493867 @default.
• W89277110 hasConcept C62112901 @default.
• W89277110 hasConcept C81885089 @default.
• W89277110 hasConcept C86803240 @default.
• W89277110 hasConcept C95444343 @default.
• W89277110 hasConceptScore W89277110C104317684 @default.
• W89277110 hasConceptScore W89277110C127561419 @default.
• W89277110 hasConceptScore W89277110C1491633281 @default.
• W89277110 hasConceptScore W89277110C153911025 @default.
• W89277110 hasConceptScore W89277110C159654299 @default.
• W89277110 hasConceptScore W89277110C203014093 @default.
• W89277110 hasConceptScore W89277110C2522874641 @default.
• W89277110 hasConceptScore W89277110C2775954498 @default.

• next